Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.35.
A number of equities research analysts have recently weighed in on the company. HC Wainwright lowered their target price on Allogene Therapeutics from $23.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. JPMorgan Chase & Co. lowered their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Monday, September 25th. Finally, Oppenheimer reiterated an “outperform” rating and set a $28.00 price target on shares of Allogene Therapeutics in a report on Thursday, August 3rd.
Hedge Funds Weigh In On Allogene Therapeutics
Allogene Therapeutics Stock Up 1.4 %
Allogene Therapeutics stock opened at $2.99 on Tuesday. The company has a market capitalization of $503.15 million, a PE ratio of -1.33 and a beta of 0.83. The firm has a fifty day simple moving average of $3.14 and a two-hundred day simple moving average of $4.35. Allogene Therapeutics has a twelve month low of $2.31 and a twelve month high of $11.10.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
- Five stocks we like better than Allogene Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- Safeguard your portfolio with these three bargain stocks
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Membership clubs gain leverage for the consumer rebound
- How is Compound Interest Calculated?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.